21 March 2017 - The cost of treatment with ustekinumab should not exceed the drug plan cost of the least costly alternative biologic treatment option.

The CADTH Canadian Drug Expert Committee (CDEC) has recommended that ustekinumab be reimbursed for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to, loss of response to, or were intolerant to either immunomodulators or one or more tumour necrosis factor-alpha antagonists, or have had an inadequate response to, intolerance to or demonstrated dependence on corticosteroids, if the following clinical criterion and conditions are met:

• Treatment with ustekinumab should be discontinued if patients do not achieve clinical response within eight weeks of induction therapy
  
• Patients treated with ustekinumab should be under the care of a specialist physician with experience in the diagnosis and management of Crohn’s disease
  

Read CADTH recommendation for ustekinumab